Correction to : First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data
| Errataetall: |
ErratumFor: BioDrugs. 2022 Mar;36(2):137-151. - PMID 35147894 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 37(2023), 1 vom: 19. Jan., Seite 121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boussageon, Maxime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.01.2023 published: Print ErratumFor: BioDrugs. 2022 Mar;36(2):137-151. - PMID 35147894 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40259-022-00565-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349142963 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349142963 | ||
| 003 | DE-627 | ||
| 005 | 20231226041922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40259-022-00565-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349142963 | ||
| 035 | |a (NLM)36401075 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boussageon, Maxime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correction to |b First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumFor: BioDrugs. 2022 Mar;36(2):137-151. - PMID 35147894 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Swalduz, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Chouaïd, Christos |e verfasserin |4 aut | |
| 700 | 1 | |a Bylicki, Olivier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy |d 1997 |g 37(2023), 1 vom: 19. Jan., Seite 121 |w (DE-627)NLM096446870 |x 1179-190X |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:1 |g day:19 |g month:01 |g pages:121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40259-022-00565-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 1 |b 19 |c 01 |h 121 | ||